November 1, 2018
Just a short while after securing a CE Mark for its second generation device, Abbott has been granted FDA clearance for FreeStyle LibreLink, a companion mobile app for its 10 to 14-day CGM.
The launch adds a long-awaited feature for US users that’s been available for some time in Europe: users will be able to scan their sensors with an app on their smartphone — and see their latest reading —...
September 6, 2018
Diabetes is a costly chronic condition, and according to the International Diabetes Federation affects at least 425 million people worldwide. As such, it’s little surprise that an increasing number of digital health companies have spotted an opportunity to help patients manage and control their disease.
In fact, that opportunity led the total revenue digital diabetes market to triple in 2017 to $...
September 5, 2018
Correction: A previous version of this article failed to specify that the deal concerns Freestyle Libre Pro, rather than the consumer version, Freestyle Libre.
Livongo Health, the digital chronic disease management company founded by former Allscripts CEO Glen Tullman, announced today that it will be the first United States enterprise diabetes management company to bring Abbott’s Freestyle Libre...
August 23, 2018
Evidation Health is teaming up with Tidepool to launch a connected device-powered study of nocturnal hypoglycemic events in people with Type 1 diabetes.
The research is novel in that connected devices — including Dexcom continuous glucose monitors, an Emfit sleep monitor, and a WHOOP activity tracker — will allow researchers to access data about overnight low blood sugar events that previously...
August 10, 2018
Shortly after launching its integrated continuous glucose monitoring system, Dexcom announced a 42 percent increase in year-over-year sales during its Q2 earnings call.
“Not only did we exceed our annual growth guidance for the second consecutive quarter but the business continues to accelerate,” Kevin Ronald Sayers, CEO of Dexcom, said during the call. “All of our key segments demonstrated...
August 9, 2018
Not two months after getting the FDA nod for its implantable CGM, Eversense, Senseonics held its Q2 earnings call reporting a increase in year over year revenues. However, it continues to operate at a net loss.
“In a matter of just six short weeks, we’ve accomplished a lot. We’ve received the authorization from the agency to commercialize in the US, we launched our US commercial activities...
June 25, 2018
This weekend saw the kickoff of the American Diabetes Association’s 78th annual conference, and with it a slew of new data from diabetes management players. The meeting included presentation on studies covering a range of technologies, such as continuous glucose monitors, insulin pumps, apps, and other digital-backed management strategies.
Among the studies highlighted by the association was an...
June 22, 2018
At long last, Eversense, the implantable continuous glucose monitoring system from Senseonics, has received FDA clearance to be marketed in the United States.
“The FDA is committed to advancing novel products that leverage digital technology to improve patient care,” FDA Commissioner Dr. Scott Gottlieb said in a statement. “These technologies allow patients to gain better control over their...
June 21, 2018
Glucose-monitoring contact lenses have been a continuing area of interest from developers all over the world. Most recently a team of researchers at Purdue University has announced that they have developed a new silicon-based, sensor-carrying contact lens that can monitor glucose levels as well as be used for ocular pain relief and drug delivery.
The group at Purdue said the technology can...
May 25, 2018
Dexcom started out the year strong following the FDA clearance of its integrated continuous glucose monitor the G6. In its Q1 earnings call, the company reported a 30 percent increase in revenue compared to Q1 of 2017, bringing its total revenue to $184 million.
When the FDA gave Dexcom the nod for the G6 it became the first interoperable CGM to get the designation. According to the earnings call...